Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

958 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy.
Schultze A, Torti C, Cozzi-Lepri A, Vandamme AM, Zazzi M, Sambatakou H, De Luca A, Geretti AM, Sonnerborg A, Ruiz L, Monno L, Di Giambenedetto S, Gori A, Lapadula G; European Transmitted Drug Resistance collaboration (EU-TDR). Schultze A, et al. Among authors: ruiz l. AIDS. 2019 Feb 1;33(2):315-326. doi: 10.1097/QAD.0000000000002046. AIDS. 2019. PMID: 30325769
Transmission of drug-resistant HIV-1 is stabilizing in Europe.
Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA. Vercauteren J, et al. Among authors: ruiz l. J Infect Dis. 2009 Nov 15;200(10):1503-8. doi: 10.1086/644505. J Infect Dis. 2009. PMID: 19835478
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme. Theys K, et al. Among authors: ruiz l. Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81. Retrovirology. 2012. PMID: 23031662 Free PMC article.
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Ruiz L, Romeu J, Martínez-Picado J, Schmit JC, Vandamme AM, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E, Clotet B. Ruiz L, et al. AIDS. 1996 Dec;10(14):F61-6. doi: 10.1097/00002030-199612000-00003. AIDS. 1996. PMID: 8970679 Clinical Trial.
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B; Havana Study Group. Tural C, et al. Among authors: ruiz l. AIDS. 2002 Jan 25;16(2):209-18. doi: 10.1097/00002030-200201250-00010. AIDS. 2002. PMID: 11807305 Clinical Trial.
958 results